Ra Pharmaceuticals Appoints John C. King as Chief Commercial Officer
April 18 2018 - 7:00AM
Business Wire
Ra Pharmaceuticals, Inc. (NASDAQ:RARX), a clinical stage
biopharmaceutical company focusing on the development of
next-generation therapeutics for the treatment of
complement-mediated diseases, today announced the appointment of
John C. King as Chief Commercial Officer, effective April 16, 2018.
Mr. King brings to Ra Pharma more than 20 years of senior, global,
commercial leadership experience within the biotechnology rare
disease space, most recently with Alexion Pharmaceuticals.
“Having led the successful launch and commercialization of
Soliris® for generalized myasthenia gravis (gMG) in the U.S. and
growth of paroxysmal nocturnal hemoglobinuria (PNH) in markets
around the world, John is ideally suited to help us build the
commercial foundation for RA101495 SC in complement-mediated
diseases,” said Doug Treco, PhD, President and Chief Executive
Officer of Ra Pharma. “With enrollment in our Phase II trial of
RA101495 SC in gMG progressing rapidly, and continued advancement
of our PNH program, we look forward to John’s contributions to the
leadership team.”
“RA101495 SC has the potential to provide patients with a more
convenient, flexible, and accessible first-line treatment for PNH,
gMG, and other lifelong, complement-mediated diseases,” said Mr.
King. “With compelling clinical data to date, strong support from
the investigator community, and a focused clinical strategy, now is
a uniquely exciting time to join the company. I look forward to
working with the talented and dedicated team at Ra Pharma to build
a plan for commercializing this promising treatment candidate.”
Mr. King comes to Ra Pharma from Alexion Pharmaceuticals, where
he served most recently as Vice President, U.S. Neurology Business
Unit. In this role, he was responsible for building and leading the
team launching Soliris® (eculizumab) for gMG in the U.S. At
Alexion, he also served as Vice President, Head of Global LAL-D
Franchise and Vice President, Head of Global PNH Franchise. Prior
to joining Alexion in 2009, Mr. King served in commercial roles of
increasing responsibility at Wyeth Pharmaceuticals. He began his
career at Ernst & Young LLP. Mr. King obtained his BS in
business logistics and labor relations and his MBA in finance and
management from Pennsylvania State University.
About Ra Pharmaceuticals
Ra Pharmaceuticals is a clinical stage biopharmaceutical
company focusing on the development of next-generation therapeutics
for complement-mediated diseases. The Company discovers and
develops peptides and small molecules to target key components of
the complement cascade. For more information, please
visit: www.rapharma.com.
Forward-Looking Statement
This press release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995, including, but not limited to, statements regarding the
potential, safety, efficacy and regulatory and clinical progress of
our product candidates, including RA101495; trial design, timeline
and enrollment of our ongoing and planned clinical programs; plans
to commercialize RA101495; and Mr. King’s anticipated contributions
to Ra Pharma. All such forward-looking statements are based on
management's current expectations of future events and are subject
to a number of risks and uncertainties that could cause actual
results to differ materially and adversely from those set forth in
or implied by such forward-looking statements. These risks and
uncertainties include the risks that Ra Pharma's product
candidates, including RA101495, will not successfully be developed
or commercialized; the risk that topline results as
of February 7, 2017 from the Company's global Phase 2
clinical program evaluating RA101495 for the treatment of PNH may
not be indicative of final study results; as well as the other
important factors discussed in the "Risk Factors" section in Ra
Pharma's most recently filed Annual Report on Form 10-K and other
risks detailed in Ra Pharma's subsequent filings with
the Securities and Exchange Commission. There can be no
assurance that the actual results or developments anticipated by Ra
Pharma will be realized or, even if substantially realized, that
they will have the expected consequences to, or effects on, Ra
Pharma. All information in this press release is as of the date of
the release, and Ra Pharma undertakes no duty to update this
information unless required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180418005173/en/
Argot PartnersInvestors:Natalie Wildenradt,
646-681-8192natalie@argotpartners.comorMedia:David Rosen,
212-600-1902david.rosen@argotpartners.com
Ra Pharmaceuticals (NASDAQ:RARX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ra Pharmaceuticals (NASDAQ:RARX)
Historical Stock Chart
From Apr 2023 to Apr 2024